Volume 3, Issue 6
Editorialp. 507
Expanding the role of cancer prevention in clinical trials design and analysis
Author(s): Graham W Warren, James R Marshall
Editorialp. 1–xxx
The importance of considering ADHD in smoking cessation clinical trials
Author(s): L Cinnamon Bidwell & Adam M Leventhal
News and Viewsp. 515
Oncology studies tend to be smaller and less robust
Therapeutic Prospectivep. 523
The role of meta-analysis in defining clinical practice in advanced non-small-cell lung cancer
Author(s): Massimo Di Maio
News and Viewsp. 531
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Author(s): Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
Special Issue Articlep. 545
Quality-adjusted survival as an end point in breast cancer trials
Author(s): AJ Martin, RJ Simes
Review: Clinical Trail Outcomesp. 557
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Author(s): Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomesp. 571
Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches
Author(s): Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild, Bernard M Corfe
Review: Clinical Trail Outcomesp. 595
Inhaled corticosteroids: the last 5 years
Author(s): Hengameh H Raissy, H William Kelly
Acknowledgementsp. 603
